Cross-sectional and dynamic change of serum metabolite profiling for Hepatitis B-related acute-on-chronic liver failure by UPLC/MS

• Published in: Journal of viral hepatitis Vol. 21; no. 1; pp. 53 - 63
• Main Authors: Nie, C. Y., Han, T., Zhang, L., Li, Y., Liu, H., Xiao, S. X., Kang, H., Liu, S. Y.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01-01-2014; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Biomarkers; Blood Chemical Analysis; Chromatography, Liquid; End Stage Liver Disease - diagnosis; End Stage Liver Disease - pathology; Female; Hepatitis; hepatitis B; Hepatitis B - diagnosis; Hepatitis B - pathology; Hepatitis B virus; Humans; Liver cirrhosis; liver failure; Male; Mass Spectrometry; Medical prognosis; Metabolites; metabolomics; Middle Aged; Mortality; Prognosis; serum; Serum - chemistry; liver failure; serum; hepatitis B; metabolomics; prognosis; biomarkers
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/jvh.12122

Summary
Summary Acute‐on‐chronic liver failure(ACLF) is an increasingly recognized entity encompassing an acute deterioration of liver function and results in the failure of one or more organs with high short‐term mortality. The focus of this study was to discover noninvasive and reliable biomarkers for the diagnosis and prognosis of hepatitis B‐related ACLF. Ultra‐performance liquid chromatography–mass spectrometry (UPLC/MS) was used to analyse serum metabolites of 28 patients with hepatitis B‐related ACLF, 35 patients with Child‐Pugh A cirrhosis, 30 patients with chronic hepatitis B and 35 healthy volunteers (HS). Characteristic metabolites were screened, identified and dynamically tracked to investigate their value for diagnosis and prognosis. After comparing serum metabolic profile of hepatitis B‐related ACLF and Child‐Pugh A cirrhosis, 99 characteristic metabolites were selected, and 38 of them were identified. Dynamic tracking model demonstrated that 17 metabolites were related to prognosis of hepatitis B‐related ACLF, and there were also 11 metabolites which improved with treatment in the survival group. The correlations between these characteristic metabolites and the model for end‐stage liver disease score were strong. These observations contributed to the investigation of the mechanisms of hepatitis B‐related ACLF manifestation and progression on the metabolic level, and they provided information for the identification of biomarkers for the diagnosis and prognosis of hepatitis B‐related ACLF.